lpca Laboratories enters into Technology Transfer Agreement with Omexa Formulary
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
The agreement sets terms under which POC will manufacture the product or receive royalties
HIFU is a state-of-the-art treatment that utilizes high-frequency sound waves to target and destroy prostate cancer cells
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Reinforces Henkel commitment to supporting customers and ecosystem in medical healthcare
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
The non-enzymatic electrochemical sensing strip can simultaneously detect the direct and total bilirubin in a single drop of blood, and provide the concentrations within a minute
Subscribe To Our Newsletter & Stay Updated